Strategic partnerships Identify collaboration opportunities with academic and clinical partners involved in metabolic and cortisol-related research, such as departments at Oxford, Sheffield, and Worcester College, to accelerate trial recruitment, access specialized patient cohorts, and co‑develop biomarkers for clofutriben.

Clinical trial expansion Target outreach to endocrinology and primary care networks to support ongoing and upcoming trials (CAPTAIN‑T2D and DC‑MACS related studies) and explore investigator‑initiated studies, expanding site reach and patient enrollment.

Rare/metabolic focus Position clofutriben as a novel solution for patients with treatment-resistant metabolic dysfunction, highlighting the first‑in‑class HSD‑1 inhibition to attract specialty pharmacies, payer partnerships, and value‑based care discussions around cortisol‑related metabolic disorders.

Financing to commercialization Leverage recent Series B financing and new board seats to pursue strategic licensing, co‑development, or regional commercialization deals, especially in markets with high diabetes burden and cardiometabolic risk.

Engagement pipeline Develop a targeted outreach plan to biotech and pharma firms with cardiovascular/metabolic portfolios for potential in‑license or collaboration opportunities, leveraging the leadership team’s expertise and the company’s precision medicine focus.